SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 66 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,409,114 | -25.8% | 303,658 | +7.0% | 0.00% | -100.0% |
| Q2 2023 | $5,941,335 | -36.8% | 283,867 | -36.2% | 0.00% | 0.0% |
| Q1 2023 | $9,401,970 | +38.0% | 445,169 | +66.3% | 0.00% | 0.0% |
| Q4 2022 | $6,813,270 | -6.2% | 267,712 | -11.4% | 0.00% | 0.0% |
| Q3 2022 | $7,260,000 | +399.0% | 302,128 | +299.5% | 0.00% | – |
| Q2 2022 | $1,455,000 | -26.3% | 75,634 | -33.5% | 0.00% | – |
| Q1 2022 | $1,975,000 | -52.2% | 113,655 | -39.8% | 0.00% | – |
| Q4 2021 | $4,135,000 | +140.0% | 188,937 | +109.5% | 0.00% | – |
| Q3 2021 | $1,723,000 | +205.5% | 90,177 | +174.6% | 0.00% | – |
| Q2 2021 | $564,000 | -75.5% | 32,837 | -68.2% | 0.00% | – |
| Q1 2021 | $2,305,000 | +122.3% | 103,111 | +121.1% | 0.00% | – |
| Q4 2020 | $1,037,000 | +174.3% | 46,627 | +82.0% | 0.00% | – |
| Q3 2020 | $378,000 | -44.3% | 25,626 | -44.1% | 0.00% | – |
| Q2 2020 | $679,000 | +130.2% | 45,822 | +70.3% | 0.00% | – |
| Q1 2020 | $295,000 | +2.8% | 26,899 | -17.5% | 0.00% | – |
| Q4 2019 | $287,000 | +21.6% | 32,622 | +3.1% | 0.00% | – |
| Q3 2019 | $236,000 | -36.4% | 31,655 | -20.7% | 0.00% | – |
| Q2 2019 | $371,000 | -36.3% | 39,911 | -64.1% | 0.00% | – |
| Q1 2019 | $582,000 | -42.9% | 111,049 | -51.5% | 0.00% | – |
| Q4 2018 | $1,019,000 | +114.5% | 229,091 | +289.7% | 0.00% | – |
| Q3 2018 | $475,000 | +141.1% | 58,786 | +109.3% | 0.00% | – |
| Q2 2018 | $197,000 | +629.6% | 28,084 | +1382.0% | 0.00% | – |
| Q1 2018 | $27,000 | -38.6% | 1,895 | -62.6% | 0.00% | – |
| Q4 2017 | $44,000 | +633.3% | 5,062 | +900.4% | 0.00% | – |
| Q3 2017 | $6,000 | +50.0% | 506 | +67.0% | 0.00% | – |
| Q2 2017 | $4,000 | -63.6% | 303 | -63.7% | 0.00% | – |
| Q1 2017 | $11,000 | +120.0% | 834 | +28.9% | 0.00% | – |
| Q4 2016 | $5,000 | -64.3% | 647 | -23.7% | 0.00% | – |
| Q3 2016 | $14,000 | +1300.0% | 848 | +852.8% | 0.00% | – |
| Q2 2016 | $1,000 | – | 89 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |